Integral DiagnosticsASX:IDX -0.50%73 Days Payable is 393.32 as of Dec. 2025, which is 145% above its 10-year median of 160.62. GuruFocus rates ASX:IDX with a GF Score™ of 73/100 and a GF Value™ of A$2.78 (Modestly Undervalued). The stock has 9 warning signs investors should review. Among 190 Medical Diagnostics & Research companies, Integral Diagnostics ranks better than 90% on this metric.
The historical rank and industry rank for Integral Diagnostics's Days Payable or its related term are showing as below:
ASX:IDX'
s Days Payable Range Over the Past 10 Years
Min: 99.71 Med: 160.62 Max: 519.02
Current: 519.02
During the past 10 years, Integral Diagnostics's highest Days Payable was 519.02. The lowest was 99.71. And the median was 160.62.
ASX:IDX's Days Payable is ranked better than 90% of 190
companies
in the Medical Diagnostics & Research industry
Industry Median: 67.275
vs ASX:IDX: 519.02
Integral Diagnostics's Days Payable
declined
from Dec. 2024 (617.93) to Dec. 2025 (393.32).
It may suggest that Integral Diagnosticsaccelerated paying its suppliers.
Integral Diagnostics Days Payable Related Terms
Integral Diagnostics Days Payable Historical Data
* Premium members only.
The historical data trend for Integral Diagnostics's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:IDX vs TMO, DHR, IDXX: Days Payable Comparison
For the Diagnostics & Research subindustry, Integral Diagnostics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Integral Diagnostics Days Payable vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Integral Diagnostics's Days Payable distribution charts can be found below:
* The bar in red indicates where Integral Diagnostics's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Integral Diagnostics's Days Payable for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Integral Diagnostics (ASX:IDX) has a Days Payable of 393.32 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Integral Diagnostics and its competitors. This is 145% above median its historical median of 160.62. Over the past decade, Integral Diagnostics' Days Payable has ranged from 99.71 to 519.02. According to the industry distribution chart, Integral Diagnostics ranks #19 out of 190 companies in the Medical Diagnostics & Research industry, placing it in the top 10%.
Is Integral Diagnostics' Days Payable too high?
Integral Diagnostics' current Days Payable of 393.32 is 145% above median its 10-year median of 160.62. Over the past 10 years, this metric has ranged from a low of 99.71 to a high of 519.02. The Medical Diagnostics & Research industry median Days Payable is 67.28. Integral Diagnostics' value of 393.32 is 484.6% above this industry median. Based on the distribution chart, Integral Diagnostics ranks #19 out of 190 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Integral Diagnostics has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Integral Diagnostics' Days Payable compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Integral Diagnostics ranks #19 out of 190 companies for Days Payable. This places Integral Diagnostics in the top 10% of its industry — outperforming the majority of peers. The industry median Days Payable is 67.28. Integral Diagnostics' value of 393.32 is 484.6% above this benchmark. Historically, Integral Diagnostics' own Days Payable has ranged from 99.71 to 519.02 over the past decade. While the company's 10-year median is 160.62 vs. the industry median of 67.28, Integral Diagnostics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Diagnostics & Research company?
The median Days Payable among Medical Diagnostics & Research companies is 67.28, based on 190 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Integral Diagnostics's current Days Payable of 393.32 is 484.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Integral Diagnostics and its competitors. For the Medical Diagnostics & Research industry, the median Days Payable is 67.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Integral Diagnostics's current Days Payable is 393.32, which is 145% above median its own 10-year median of 160.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Integral Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Integral Diagnostics (ASX:IDX) is currently considered Modestly Undervalued. The stock's GF Value™ is A$2.78, compared to a current price of A$2.00 — trading 28.1% below its estimated fair value. The current Days Payable is 393.32, which is 145% above median its 10-year median of 160.62 and 484.6% above the Medical Diagnostics & Research industry median of 67.28. Integral Diagnostics' overall GF Score™ is 73/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Integral Diagnostics (ASX:IDX), the current Days Payable is 393.32 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Integral Diagnostics (ASX:IDX) Overvalued in 2026?
Based on GuruFocus' analysis, Integral Diagnostics stock appears to be undervalued.
The current stock price of A$2.00 is trading 28.1% below its estimated GF Value™ of A$2.78.
GuruFocus considers Integral Diagnostics to be Modestly Undervalued.
Key valuation signals for ASX:IDX:
Days Payable: 393.32 (145% above median its 10-year median of 160.62)
GF Value™: A$2.78 vs. price of A$2.00 (28.1% below fair value)
Industry Position: 484.6% above the Medical Diagnostics & Research median (#19 of 190)
No single metric tells the full story. See the ASX:IDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Integral Diagnostics is a major Australian diagnostic imaging provider. In Australia, imaging revenues are almost entirely earned via the public health Medicare system. Integral typically earns approximately 90% of group revenue from diagnostic imaging in Australia and the remainder from diagnostic imaging in Auckland, New Zealand. In Australia, Integral services regional areas in Queensland, Victoria, New South Wales, and Western Australia.
73GF Score
Get the complete analysis for ASX:IDX
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:IDX has been successfully added to your 
